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Chemotherapy for Relapsed Small Cell Lung Cancer:
A Systematic Review and Practice Guideline
Susanna Cheng, MD,* William K. Evans, MD,† Denise Stys-Norman, PgDip,‡
Frances A. Shepherd, MD,§ and the Lung Cancer Disease Site Group of Cancer Care Ontario’s
Program in Evidence-based Care
Purpose: This clinical practice guideline, based on a systematic
review, evaluates chemotherapy options for patients with relapsed
small cell lung cancer (SCLC).
Methods: Relevant randomized trials and meta-analyses were iden-
tified through a systematic search of the literature. External feedback
was obtained from practitioners in Ontario, and the guideline was
approved by the provincial lung cancer disease site group.
Results: Six randomized trials met the eligibility criteria and were
included for review. One randomized phase III trial of oral topotecan
versus no treatment in patients receiving best supportive care found
topotecan to have a significant benefit in terms of 6-month survival
and quality of life. A randomized phase III trial compared outcomes
of carboplatin in patients receiving a combination of etoposide and
cisplatin (EP) and found no significant improvement associated with
carboplatin, although it was associated with significantly higher
grade 3/4 thrombocytopenia. Two randomized trials directly com-
pared chemotherapy regimens (intravenous [IV] topotecan versus
cyclophosphamide, doxorubicin, and vincristine (CAV); and bis-
chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophospha-
mide (BTOC) versus EP), but these trials found no significant
differences in terms of disease response or survival. IV topotecan
was associated with significantly higher toxicities (grade 4 throm-
bocytopenia and grade 3/4 anemia) and greater improvement in
patient-reported symptoms compared with CAV. Two randomized
trials of topotecan-treated patients comparing route of administra-
tion (IV versus oral) found no significant differences in terms of
disease response, survival, or quality of life, although oral admin-
istration was associated with increased grade 3 or 4 diarrhea in both
trials.
Conclusion: Evidence on the clinical benefit of second-line therapy
in SCLC is limited. Topotecan is the most studied agent in this
population; it has a response and survival benefit in comparison with
placebo, but it also has greater toxicity in comparison with CAV. To
date, significant differences in terms of response and survival are not
evident in studied chemotherapy options.
Key Words: Small cell lung cancer, Chemotherapy, Relapsed,
Re-treatment, Systematic review.
(J Thorac Oncol. 2007;2: 348–354)
Lung cancer is the most common cause of cancer-relateddeaths in men and women. Approximately 15% to 20% of
lung cancers are of the small cell type. Small cell lung cancer
(SCLC) has a very aggressive course, with approximately
60% to 70% of patients having disseminated (extensive stage)
disease at presentation.1 SCLC is initially very sensitive to
chemotherapy, with 60% to 90% of patients with limited-
stage disease responding to first-line therapy with cyclophos-
phamide, doxorubicin, and vincristine (CAV) or etoposide
and cisplatin (EP), and 40% to 70% of patients achieving a
complete response (CR).1 Despite the high rate of response,
median survival ranges from 12 to 20 months, with only 6%
to 12% of patients living beyond 5 years. Overall response
rates (CR and partial response [PR]) are lower for patients
with extensive-stage disease and range from 40% to 70%.
Survival is also shorter in this population, with median
survival ranging from 7 to 11 months, and fewer than 5% of
patients living beyond 2 years.1
Patients with SCLC who relapse or progress after
first-line chemotherapy have a poor prognosis. Median sur-
vival is 2 to 3 months for patients who do not receive
second-line therapy. Second-line chemotherapy produces tu-
mor regression. Nevertheless, in the majority of patients,
these responses tend to be short lived, and the median
survival, even for treated patients, is rarely more than 6
months.
Three categories of disease have been described in the
literature regarding the response to initial chemotherapy and
the duration of response: sensitive, resistant, and refractory.
“Sensitive” refers to patients who have had a tumor response
lasting 90 days or longer. These patients are thought to have
the greatest potential for benefit from second-line chemother-
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apy. “Resistant” refers to patients who have recurred within
90 days of completing primary therapy. “Refractory” refers to
patients with tumors that never responded to first-line therapy
or to those who progressed during first-line therapy. Whether
patients with refractory or resistant SCLC benefit from sec-
ond-line therapy remains a source of controversy. There is a
need to develop better treatments for patients with relapsed
SCLC. The purpose of this evidence-based report is to eval-
uate the evidence for relapsed SCLC, to determine the most
effective therapies for this patient population. Specifically,
our goal was to answer the following questions: in patients
with relapsed SCLC, does chemotherapy improve survival
and quality of life (QOL)? Which single agent or combination
chemotherapy regimen is most effective in the treatment of
relapsed SCLC?Which patients with relapsed SCLC are most
likely to benefit from additional chemotherapy? This report
presents evidence that is based on our systematic review.
Treatment recommendations based on feedback from Ontario
practitioners are also provided.
METHODS
This systematic review and practice guideline was de-
veloped by Cancer Care Ontario’s Program in Evidence-
based Care (PEBC), using the Practice Guidelines Develop-
ment Cycle methodology.2 This report is intended to promote
evidence-based practice. This report has been edited and
condensed for publication; the unabridged version is avail-
able on the PEBC section of the Cancer Care Ontario Web
site at http://www.cancercare.on.ca.
Literature Search Strategy
A systematic search for relevant evidence from the
following databases was conducted: MEDLINE (1985 to
October 2005), CANCERLIT (1985 to March 2002), and the
Cochrane Library (2005, issue 4). Conference proceedings,
including those from the American Society of Clinical On-
cology (1997–2005) and the International Association for the
Study of Lung Cancer (2005), were also searched. Further,
the Canadian Medical Association Infobase and the National
Practice Guidelines Clearinghouse were searched for existing
evidence-based practice guidelines. The National Cancer In-
stitute clinical trials database was also searched for reports of
new or ongoing trials. The complete literature search strategy
is available on the Cancer Care Ontario Web site.
Study Selection Criteria
Full reports and abstracts were selected for inclusion if
they were randomized trials (phase II or III) that compared
chemotherapy versus no chemotherapy or compared different
chemotherapy regimens as second-line treatment for SCLC.
Reports were also required to provide survival or response
rate data. A search of evidence-based practice guidelines,
systematic reviews, and meta-analyses of randomized trials
on chemotherapy for patients with relapsed SCLC was also
conducted. Non-English trials, trials with a primary focus on
first-line treatment, and those that included a mix of untreated
and previously treated patients were excluded.
Synthesizing the Evidence
The data from the randomized trials were not pooled,
because treatment comparisons were too heterogeneous to
allow for meaningful evaluation.
External Review and Approval
After review and approval of the draft report by the
provincial lung disease site group and the PEBC’s report
approval panel, the draft guideline and a mailed survey were
sent to practitioners in Ontario, Canada for feedback. This
external review process allows practitioners to comment on
the quality of the draft report and recommendations, whether
the draft recommendations should serve as a practice guide-
line, and whether respondents would use the practice guide-
line in their own practice. Written comments are also encour-
aged and are considered during the final revision of the
guideline.
RESULTS
Literature Search Results
Four fully published randomized trials3–7 and two trials
published in abstract form8,9 met the eligibility criteria for
this systematic review. Comparisons included different sec-
ond-line chemotherapy regimens,5–7 chemotherapy versus
best supportive care (BSC),3,4 and different treatment regi-
mens of single-agent chemotherapy.8,9 Trial descriptions and
outcomes are outlined in Table 1. No eligible systematic
reviews or evidence-based clinical practice guidelines were
identified.
Outcomes
Chemotherapy versus BSC
One open-label phase III trial randomized 141 patients
receiving BSC who were ineligible for further intravenous
(IV) chemotherapy to oral topotecan or no treatment.3 Pa-
tients were stratified by performance status (PS), gender,
presence of liver metastases at baseline, and time to progres-
sion from the end of chemotherapy. The final analysis yielded
80% statistical power for the primary outcome, which was
overall survival. The median dose intensity of oral topotecan
achieved was 3.77 mg/m2 per week, which represented 98%
of the scheduled dose.
Tumor Response and Survival
The overall response rate for oral topotecan and BSC
was 7% (95% CI 2.33%–15.67%), although no patients
achieved a CR. The stable disease rate was 44% (31 of 77
patients) for patients receiving topotecan. A comparison of
survival outcomes revealed a statistically significant benefit
for oral topotecan and BSC compared with BSC alone (un-
adjusted hazard ratio [HR]  0.64, 95% CI  0.45–0.90;
adjusted HR  0.61, 95% CI  0.43 to 0.87). Six-month
survival rates were 48.8% for the combined treatment com-
pared with 25.7% for BSC alone; median survival was 25.9
and 13.9 weeks for the treatment and BSC groups, respec-
tively. Subgroup analyses demonstrated a significant survival
benefit for patients with a time to progression of 60 days
(23.3 versus 13.2 weeks, p 0.0357) but not for patients with
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a time to progression of 60 days (28 versus 14 weeks, p 
0.0975; data reported only in abstract).4 The absence of a
significant result in this later subgroup may be attibutable to
a lack of statistical power, because accrual was not planned
around this particular analysis.
Toxicity
Table 2 outlines grade 3/4 toxicities for all included trials.
Neutropenia was the most common toxicity, with 61% of pa-
tients in the topotecan group reporting grade 3/4 toxicity. Grade
3/4 diarrhea (6%) and fatigue (4%) were the most commonly
reported nonhematological adverse events in this group. In
patients receiving BSC alone, pain (6%), dyspnea (9%), and
fatigue (4%) were the most common adverse events.4 All-cause
mortality 30 days after randomization was 7% for the combined
group compared with 13% for BSC alone.
QOL
The standardized EuroQoL Group EQ-5D question-
naire was used to measure QOL at baseline and at 3-month
intervals. The difference between topotecan and BSC versus
BSC alone in the rate of change per 3-month interval using
the EQ-5D questionnaire was 0.15 (95% CI  0.05 to 0.25),
demonstrating that the EQ-5D score worsened faster in the
BSC arm.3
Second-Line Chemotherapy Regimens
Sculier et al.5 randomized 72 patients, stratified by
center, PS, and disease-free interval, to EP with or without
carboplatin (Cb) as second-line therapy and compared re-
sponse and survival as a primary outcome. Of these, a total of
59 patients were assessable for response. An imbalance
between treatment groups in the number of patients excluded
suggests that these trial results should be interpreted with
caution. Sculier et al.5 also excluded patients if their prior
chemotherapy regimen contained a platinum or etoposide;
therefore, this trial is less relevant for current practice.
Two trials evaluated response rate as a primary out-
come. Von Pawel et al.6 randomized 211 patients, stratified
by extent of disease and PS, to IV topotecan or to CAV.
O’Bryan et al.7 randomized 103 patients to bis-chloro-eth-
ylnitrosourea, thiotepa, vincristine, and cyclophosphamide
(BTOC) or EP; they also report on an additional 26 nonran-
domized eligible patients who were treated with EP.
Two trials describe the randomization process,6,7 and
one reports the method of sample size determination.6 None
of the trials report on the blinding of treatment assignment for
patients or physicians; nevertheless, in the trial by von Pawel
et al.,6 independent radiologists blinded to treatment assign-
ment reviewed the radiographs of all responders. One trial
reports pharmaceutical support.6
Tumor Response and Survival
None of the trials examining different second-line che-
motherapy regimens detected a statistically significant differ-
ence in tumor response or survival between treatment
arms.5–7 The trial by Sculier et al.5 was not powered to assess
TABLE 2. Grade 3/4 Toxicities for Randomized Trials
Reference Treatment Neutropenia Leukopenia Thrombocytopenia Anemia Nausea/vomiting Diarrhea
Chemotherapy versus BSC
O’Brien et al.3,4 PO topo  BSC 61% NR 37% 25% 1%/3% 6%
BSC 11% 4% 6% 0 0%
Comparing different second-line chemotherapy regimens
Sculier et al.5 EP NR 58% 16% NR 6% NR
EPCb 53% 35% 0%
p  0.97 p  0.09 p  0.22
von Pawel et al.6 CAV 87%a 81%a 15%a 20%a 6%/3% 0%
Topo 88%a 87%a 58%a 42%a 4%/2% 1%
p  0.001
(Grade 4)b
p  0.001
(Grade 4)
p  0.001
O’Bryan et al.7 EP NR 14% 9% NR 0% NR
BTOC 9% 16% 0%
Comparing different administration of second-line single-agent chemotherapy
Eckardt et al.8 PO topo 47%c NR 28.7%c 22.6% 3.9%/3.3% 7.9%
IV topo 64%c 18%b 30.7% 2.6%/2% 1.3%
p  0.05 p  0.05
von Pawel et al.9 PO topo 56.9% 45.1% 53% 31.4% 0%/11.5% 7.7%
IV topo 94.2% 73.6% 49% 30.2% 0%/3.7% 0
p  0.001
(Grade 4)
BSC, best supportive care; BTOC, bis-chloro-ethylnitrosourea, thiotepa, vincristine, cyclophosphamide; CAV, cyclophosphamide, doxorubicin, vincristine; EP, etoposide,
cisplatin; EPCb, etoposide, cisplatin, carboplatin; IV, intravenous; NR, not reported; PO, oral; topo, topotecan.
a Calculated on the basis of the number of patients with laboratory data available.
b Statistical analyses for courses, not by patient.
c Grade 4 toxicity.
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survival differences, and median survival was 18.7 weeks for
EP and 33.1 weeks for EP  Cb (p  0.11). Sculier et al.5
report response rates of 47% in the combined arm versus 29%
in the EP-alone arm. Survival was not significantly different
(7.4 months versus 7.7 months) when analyzed by the treat-
ment-free interval between first-line and second-line treat-
ment (3 versus 3 months), regardless of the treatment
arm. Nevertheless, patients who responded to first-line treat-
ment and who had experienced a treatment-free interval of
more than 3 months had significantly higher response rates
than patients with a treatment-free interval of less than 3
months.5
Von Pawel et al.6 report similar median survival rates
for patients treated with topotecan (25.0 weeks) and CAV
(24.7 weeks) (p  0.795). In this trial, the response rate for
patients receiving topotecan was 24.3%, compared with
18.3% for CAV. A Cox regression analysis, which adjusted
for the effects of multiple possible predictive variables on
survival, was statistically significant for baseline PS and
extent of disease (p  0.001). O’Bryan et al.7 investigated
different dose schedules for patients who were assessed as
good risk or poor risk. The median survival was 13 weeks for
patients receiving BTOC (10 weeks for good risk and 14
weeks for poor risk) and 16 weeks for patients treated with
EP (35 weeks for good risk and 12 for poor risk). A subgroup
analysis detected a statistically significant survival difference
between the two arms in the good-risk patients (p  0.01) in
favor of treatment with EP. The response rate was 13% (six
PR) in the BTOC arm and 12% (one CR, six PR) in the EP
arm. Response rates are not reported for the 26 nonrandom-
ized patients.
The observed differences between the von Pawel et al.6
and O’Bryan et al.7 trials in terms of response rates and
survival may be attributable to differences in the patient
populations. Most patients in the trial by von Pawel et al.6 had
received platinum-based first-line chemotherapy (77%–79%)
and had all responded to first-line chemotherapy, with most
patients relapsing more than 60 days after initial treatment.
The majority of patients also exhibited a good PS (Eastern
Cooperative Oncology Group [ECOG] PS 0–1, 79%).6 Nev-
ertheless, in the trial by O’Bryan et al.,7 most patients (72%)
received CAV or single-agent etoposide as first-line treat-
ment, with a median treatment-free interval of only 6 weeks
and a generally poor PS (Karnofsky 2–3, 56%).
Toxicity
Sculier et al.,5 report comparable toxicity between
treatment arms, except for grade 3 or 4 thrombocytopenia,
which was more common with the Cb regimen (35% versus
16%, p  0.09). Infections are reported for 3% of patients
overall, and there was one treatment-related death in the EP arm.
A similar incidence of grade 4 neutropenia has been
reported by von Pawel et al.6 in both treatment arms (topo-
tecan, 70.2%; CAV, 71.7%); rates of grade 4 neutropenic
infections were also substantial (topotecan, 28%; CAV,
26%). Nevertheless, significantly more grade 4 thrombocy-
topenia (57.6% versus 14.9%, p  0.001) and grade 3/4
anemia (42.3% versus 19.8%, p  0.001) occurred in the
topotecan arm. Transfusions were more frequently required
in patients treated with topotecan and included platelet trans-
fusions (19.6% versus 1.9% of patients) and red blood cell
transfusions (52.3% versus 26.9% of patients, p  0.001).
There were seven treatment-related deaths associated with
myelosuppression and infection: four in the topotecan group and
three in the CAV group. Three additional deaths were possibly
treatment related: two associated with topotecan (acute respira-
tory insufficiency and intracerebral hemorrhage) and one asso-
ciated with CAV (disease progression coincident with renal
failure and pancytopenia). Twenty patients withdrew from study
treatment because of treatment-related toxicity: 10 in the topo-
tecan group and 10 in the CAV group.6
O’Bryan et al.7 report grade 4 neutropenia in 8.9% of
patients treated with BTOC and in 13.6% of patients treated
with EP. They report thrombocytopenia in 15.5% and 8.6%
of patients for the BTOC and EP treatment groups, respec-
tively. Parethesias are reported for 12 patients (15%) treated
with EP and for four patients (9%) receiving BTOC. There
were three treatment-related deaths: two from infection and
myelosuppression (one in each group) and one in the EP
group from gastrointestinal bleeding associated with throm-
bocytopenia. The 26 nonrandomized patients from the EP
group are included in the toxicity results.
QOL
QOL was not assessed in any of the trials that compared
different second-line chemotherapy regimens. Nevertheless,
von Pawel et al.6 assessed disease-related symptoms on a
patient-reported nine-point scale. Symptom improvement
was significantly greater for patients receiving topotecan,
with improvements reported in dyspnea (p  0.002), hoarse-
ness (p  0.043), fatigue (p  0.032), anorexia (p  0.042),
and interference with daily activities (p  0.023). Also, the
length of time to worsening dyspnea and anorexia were
superior in the topotecan group (p  0.046 and 0.003,
respectively).
Administration of Second-Line Single-Agent
Chemotherapy
One phase III randomized trial and one phase II ran-
domized trial compared the administration of oral versus IV
topotecan.8,9 The phase III trial by Eckardt et al.8 has been
published in abstract form only and provides limited data on
which to assess the trial quality. This trial, in which 304 patients
were randomized, reports initial findings on the effectiveness of
administering oral topotecan versus IV topotecan,8 whereas the
phase II trial by von Pawel et al.9 (n  106) focused on the
efficacy of administration. Neither trial describes the random-
ization process in detail. In the phase III trial, the sample size
was determined on the basis of feasibility of study completion,
and patients were stratified by response duration to prior che-
motherapy, gender, and presence or absence of liver metastases.8
In the phase II trial, patients were stratified according to extent
of disease, duration of response to prior chemotherapy, and
presence or absence of liver metastases.9 Response was the
primary outcome in the phase III trial,8 and response, response
duration, and time to progression were the primary objectives of
the phase II trial.9 Although neither trial reports on the blinding
of treatment assignment for patients or physicians, both trials
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report that the independent radiologist reviewing the radiographs
was blinded as to whether patients had received oral or IV
topotecan. Both trials report receiving pharmaceutical support.
The median number of courses of topotecan administered was
four in both arms of the two studies.8,9
Tumor Response and Survival
Eckardt et al.8 report an overall response rate of 18.3%
(2 CR and 26 PR) for patients treated with oral topotecan and
21.9% (33 PR) for patients receiving IV topotecan. One-year
survival rates were 33% and 29%, respectively, and median
survival was 33 and 35 weeks (oral versus IV, respectively)
(HR  0.98; 95% CI  0.77–1.25). Von Pawel et al.9 report
an overall response rate of 23.1% (1 CR and 11 PR) for oral
administration and 14.8% (two CR and six PR) for IV
administration, with median overall survival of 32.3 and 25.1
weeks (risk ratio  0.84; 95% CI  0.53–1.32), respectively.
Factors associated with longer survival in a Cox regression
analysis were absence of baseline liver metastases (p 
0.001) and better PS (0 or 1 versus 2, p  0.025).
Toxicity
Eckardt et al.8 report significantly more treatment-
related grade 4 neutropenia in patients treated orally versus
those treated intravenously (64.2% versus 47%, p  0.05).
They report febrile neutropenia in 4.6% and 7.3% for the oral
group versus the IV group, respectively. The incidence of
diarrhea was significantly higher in the oral group (7.9%
versus 1.3%, p 0.05). Infection is reported for both the oral
and IV groups (9.8% versus 7.9%, respectively), as are sepsis
(2.6% versus 3.3%) and dehydration (3.9% versus 1.3%).
There were 10 treatment-related deaths: six (4%) in the oral
group and four (3%) in the IV group.
Von Pawel et al.9 note toxicity in both arms of their
study. Grade 3 or 4 neutropenia was present in 56.9% of the
patients treated orally versus 94.2% of patients treated intra-
venously. Of the patients on oral therapy, 9.6% experienced
grade 3/4 dyspnea compared with 9.3% on IV therapy.
Incidences of grade 3/4 fever, pneumonia, and diarrhea were
greater in the oral topotecan arm (5.8%, 7.7%, and 7.7%)
compared with the IV arm (1.9%, 0%, and 0%). Grade 5
dyspnea and pneumonia are reported in two patients treated
with IV topotecan, and one patient in the oral arm experi-
enced grade 5 fever. Grade 5 pulmonary embolism occurred
in 3.8% of oral therapy and 1.9% of the IV therapy patients.
Red blood cell transfusions were administered in 42.3% and
38.9% of oral and IV patients, respectively, and platelet
transfusions were administered in 13.5% and 14.8% of pa-
tients, respectively. There were two treatment-related deaths
in the oral topotecan arm.
QOL
Eckardt et al.8 did not find a statistically significant
difference in QOL as assessed by the Functional Assessment
of Cancer Therapy-Lung, Trial Outcome Index, individual
well-being, or individual symptom scores.8 Von Pawel et al.9
also assessed QOL but used a nonvalidated instrument that
was based on the Lung Cancer Symptom Score. Patients’
self-assessed symptoms were measured at baseline and im-
mediately before the next therapy. Patients who had initially
reported symptoms in the oral and IV topotecan groups
reported symptomatic improvement in chest pain (42.1% and
31.8% of patients), hemoptysis (33.3% and 40%), insomnia
(32% and 26.6%), hoarseness (35.7% and 37.5%), and inter-
ference with daily activity (25.8% and 22.2%), respectively.
External Review Results
Before initiation of the external review process, con-
sensus on the recommendations was obtained from the pro-
vincial lung disease site group members, and the guideline
report was then reviewed and approved by the PEBC report
approval panel. Feedback was then obtained through a mailed
survey of 34 medical oncologists and 23 radiation oncologists
in Ontario. The survey consisted of items evaluating the
methods, results, and interpretive summary used to inform the
draft recommendations and whether the draft recommenda-
tions should be approved as a practice guideline. Of the 29
responses received (51% response rate), 16 practitioners
indicated that the report was relevant to their clinical practice,
and they completed the survey. Of these, 75% (12/16)
strongly agreed or agreed with the draft recommendations as
stated, 80% (12/15) agreed that the report should be approved
as a practice guideline, and 67% (10/16) said they would be
likely or very likely to use the guideline in their own practice.
Comments received through external review were considered
in the final practice guideline.
DISCUSSION
Evidence for the clinical benefit of second-line chemo-
therapy in the treatment of patients with relapsed SCLC is
limited. The recently published randomized phase III trial of
topotecan and BSC versus BSC alone is the first to demon-
strate a significant improvement in overall and median sur-
vival and QOL in patients with relapsed, resistant SCLC,
favoring treatment with topotecan and BSC.3 In addition,
symptom control was also substantially improved.
Three randomized trials have compared different che-
motherapy regimens.5–7 No statistically significant differ-
ences in median survival were found in these trials. The
difference in survival between the two phase III trials6,7 is
likely attributable to differences in the patient populations.
Most patients in the study by O’Bryan et al.7 had received
either CAV or etoposide alone as first-line therapy, the
median time from last treatment was only 6 weeks, and the
patients generally had poor PS. Nevertheless, most patients in
the trial by von Pawel et al.6 received platinum-based first-
line chemotherapy, had responded to first-line chemotherapy
(with most relapsing more than 60 days after initial treat-
ment), and exhibited good PS. The poorer prognostic factors
exhibited by patients in the O’Bryan et al.7 trial might explain
the lesser degree of benefit from therapy found in this trial.
Further, the trial by O’Bryan et al.7 is less relevant to
recommendations for second-line therapy in SCLC in North
America today, because first-line SCLC patients are currently
treated with EP. The study by Von Pawel et al.6 was the only
one to report improvement (though not statistically signifi-
cant) in symptom management with topotecan compared with
CAV. Nevertheless, the scoring system for this measure was not
validated. Nonetheless, on the basis of the demonstrated im-
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provement in cancer-related symptoms found in the von Pawel
et al.6 trial, the U.S. Food and Drug Administration has approved
single-agent IV topotecan as a therapy for relapsed SCLC.
There is no clinical evidence to suggest that combina-
tion chemotherapy regimens are superior to single-agent
regimens in the treatment of relapsed SCLC. Only one phase
III study has compared combination therapy (CAV) with a
single-agent (topotecan) therapy, and response rates and me-
dian survival were equivalent between the trial arms.6 Nev-
ertheless, there was more hematologic toxicity and a greater
need for transfusion in the topotecan arm.
Eckardt et al.8 and von Pawel et al.9 report similar
response and median survival rates for oral and IV adminis-
tration of topotecan. Response rates for oral administration
were 18.3% and 23.1%, compared with 21.9% and 14.8%
among IV-treated patients. Both studies note that diarrhea
was more prevalent among patients treated with oral topote-
can than among those receiving IV administration. Neverthe-
less, neutropenia was higher in the IV arm. Both trials
conclude that oral topotecan is a viable option for patients
who are not suitable for IV therapy.
There is limited evidence for determining which patients
are most likely to benefit from second-line chemotherapy. A
poor PS and relapse within 6 weeks of completing first-line
chemotherapy (resistant disease) are generally recognized as
poor prognostic factors, predicting lower response rates and
shorter survival in SCLC. A pooled analysis, which did not meet
the criteria for inclusion in this review, was conducted on five
trials of single-agent topotecan administered at time of relapse.
This analysis compared outcomes for patients with an ECOG PS
of 0 or 1 with those with an ECOG PS 2.10 The overall
response rate for patients with PS 0 or 1 was 14% (11 CR and
42 PR) compared with 17% for PS 2 patients (3 CR and 14 PR).
Response rates were lower for patients with chemo-resistant or
refractory disease, compared with chemo-sensitive patients, re-
gardless of PS. Median survival times were 36.3, 25.4, and 16
weeks for PS 0, 1, and 2, respectively. Survival was significantly
different between PS 0/1 patients and PS 2 patients (p 
0.001).10 Thus, adequate assessment of PS is important when
evaluating treatment options for relapsed SCLC patients, be-
cause patients with poor PS may not derive meaningful benefit
from second-line treatment.
Practice Guidelines
On the basis of the evidence reviewed, the lung disease
site group has developed the following recommendations for
adult patients with relapsed SCLC:
Y The evidence for the clinical benefit of second-line
chemotherapy in the treatment of patients with relapsed
SCLC is limited. The selection of patients for treatment
with second-line therapy should be dependent on the
treatment-free interval, the extent of response to first-
line therapy, residual toxicity from first-line therapy, and
the PS of the patient.
Y There is insufficient evidence to recommend a specific
chemotherapy regimen. Nevertheless, in the opinion of
the lung cancer disease site group, patients who relapse
three or more months after having completed first-line
chemotherapy may benefit from re-treatment with the
same regimen that induced their initial response. This
would generally mean re-treatment with EP. Alternative
regimens may include CAV or Cb and etoposide.
Y Topotecan is a possible alternative for patients who
initially respond to chemotherapy and who have a re-
sponse duration of 45 days or longer.
Y Topotecan may be administered orally or intravenously.
Available evidence has not yet established a superior
mode of administration, and each has different benefits
and toxicities. Oral administration is associated with a
higher incidence of grade 3/4 diarrhea, whereas IV
administration may result in a higher frequency of grade
3/4 neutropenia.
Y There is currently no standard second-line chemother-
apy regimen for patients who fail to respond to or who
relapse shortly after first-line therapy. Clinical trials are
needed to determine the optimal treatment regimen.
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